Dr Evidence (DRE), an AI-Enabled SaaS Healthcare Insights Company, Taps Industry Experts Joseph A. Boystak as Chairman of the Board and Ameet Nathwani, MD, as Chairman of its Newly Formed Medical Strategy Advisory Board
2.6.2020 17:00:00 EEST | Business Wire | Press release
DRE is pleased to welcome Joe Boystak as Chairman of the Board and Ameet Nathwani, MD, as Chairman of its newly formed Medical Strategy Advisory Board (MSAB). These enhancements to the Company reflect the expanded need for keen guidance in this unprecedented time of convergence between expert AI-enabled technology in healthcare and the exponential growth of clinical information. DRE is dedicated to applying sophisticated data science with advanced AI to generate quicker, deeper, more nuanced regulatory-grade scientific and clinical insights for the betterment of patient outcomes.
Boystak is an experienced healthcare venture capitalist and senior healthcare investment banker having been Founding Managing Partner at Health2047 Capital Partners and Founding Managing Director, Global Life Sciences at Jefferies. He is CEO of Brightwaters Capital and is a serial co-founder/investor in biomedical, med tech, health information technology, and artificial intelligence companies with spinouts from UCLA, Johns Hopkins, Harvard/Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, among others. Boystak is also named co-inventor on 5 issued US/EU patents for first-in-class medical technology developed by Bruin Biometrics LLC, a company he co-founded and was its initial Chairman. He has served on more than a dozen corporate and non-profit boards and currently serves on the Johns Hopkins Bloomberg School of Public Health and Southern California Biomedical Council (SoCalBio) Boards.
“I am honored to join the DRE Board as its Chairman. DRE’s industry leading SaaS platform is facilitating AI-driven drug discovery as pharma and life sciences companies rapidly adopt this technology,” stated Boystak. “Our SaaS platform enables, among others, researchers and drug developers to optimize drug design, improve clinical trial effectiveness, rapidly explore repurposing of compounds, refine FDA label strategies and improve product life cycle management - thus creating substantial ROI for our clients.”
Ameet Nathwani, MD, is Chairman of the newly created MSAB, which will initially consist of five members that represent industry, specialty medical societies, regulatory, data science and patient advocacy. Dr. Nathwani’s most recent position as Executive Vice President, Chief Medical Officer and Chief Digital Officer at Sanofi provides a great framework for the MSAB to inform DRE on strategy, regulatory requirements, research and development, technology and trends in clinical care. The MSAB will also advise on healthcare ecosystem partners for DRE to collaborate with to accelerate treatments and cures.
“It is a privilege to be appointed as the Chairman of the DRE MSAB. At a time when the volume and complexity of scientific data is increasing exponentially, the AI-driven DRE platform provides a state-of-the-art tool which gives healthcare organizations the ability to deconvolute critical scientific data. This agile approach to make rigorous and rapid decisions of real-world data is critical to innovate in this dynamic century of biology,” said Ameet Nathwani, MD. “The MSAB will advise DRE on enhancing the many scientific and healthcare applications of the platform in order to best support a diverse spectrum of partners that will ultimately benefit physicians and patients.”
“With our expanded SaaS platform now including the launch of DOC Analytics™ we are that much closer to achieving our mission of democratizing sophisticated analysis of clinical studies and real-world data for researchers,” added Bob Battista, MBA, FRCPH, FRCP Edin. “We have been fortunate to be backed by a committed group of investors and Board members that Joe will now lead as we chart our next stage of growth. We are similarly privileged to have Dr. Nathwani lead our newly established MSAB. Ameet’s deep sector knowledge and passion for DRE’s SaaS platform provide an incredible basis for guiding our healthcare strategy.”
Joe Boystak and Ameet Nathwani, MD, join a distinguished group of Corporate Board members at DRE that include: Marc Rapaport, immediate past Chairman of DRE, immediate past Chairman of the Board of Cedars-Sinai Medical Center (Los Angeles), private equity investor, and former Executive Vice President and Co-Head of Capital Markets at Drexel Burnham Lambert and Jefferies; Vivek Garipalli, CEO and Co-Founder Clover Health, Co-Founder CarePoint Health, and an active investor in early stage healthcare companies, including founding investor in Flatiron; Ted Meisel, serial healthcare and technology entrepreneur, Executive Founder of AVIA, Executive Chairman of WiserCare, Senior Advisor NextEquity Partners, past Senior Advisor to the Center for Medicare and Medicaid Services (CMS), past President Yahoo Search and past CEO of Overture (acquired by Yahoo); Ananth Bhogaraju, Founder and Managing Director Seven Hills Healthcare Advisors and past Vice Chairman Americas Healthcare Investment Banking Deutsche Bank; Larry Burstein, a healthcare focused Family Office career fund manager; Bob Battista, Co-Founder and CEO DRE, serial healthcare and technology entrepreneur, past Executive Vice President at TheraCom, the first ever specialty pharmacy; and Todd Feinman, MD, Co-Founder and Chief Medical Officer DRE, Hospitalist at Cedars-Sinai Medical Center (Los Angeles) and Director of a large Independent Physician Association.
ABOUT DRE
DRE is a market leading company in the AI-enabled health technology marketplace that deploys state-of-the-art solutions to identify, synthesize, and analyze complex clinical data into actionable insights. DRE provides instant, continuous search and data analysis across critical functions of Pharmaceutical, Biotech, Life Sciences and Medical Technology companies to optimize their clinical programs. Its technology platform provides DRE's customers with a Software-as-a-Service ("SaaS") Insights Engine which empower them to make better decisions from lab to patient.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200602005298/en/
Contact information
Chris Yu
pr@doctorevidence.com
+1 (310) 595-1265
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Swedish Court Further Reschedules Delivery of Judgment in PriceRunner Vs Google Antitrust Case24.6.2026 21:55:00 EEST | Press release
Klarna Group plc (NYSE: KLAR) wishes to update investors that the Patent and Market Court in Stockholm, Sweden (Patent- och marknadsdomstolen) has again postponed publication of its judgment in the antitrust damages proceedings brought by PriceRunner, a Klarna subsidiary, against Google. The Court has rescheduled publication of its judgment from June 26, 2026 to July 1, 2026 at 13:00 CET. As with the Court's two previous notifications, the rescheduling is a procedural decision by the Court and relates solely to the timing of the judgment delivery. In its notification, the Court cited high workload as the reason for needing additional time to finalize the judgment. No inference about the outcome should be drawn from it. Important Notice The outcome of the proceedings is inherently uncertain. No assurance can be given that PriceRunner will succeed on liability or quantum. Any award would be subject to appeal by Google, to sharing arrangements with former PriceRunner shareholders and Klar
Vertex Energy Announces 6,000 bpd Group III Base Oil Expansion Project24.6.2026 17:00:00 EEST | Press release
Vertex Energy, Inc. (“Vertex” or the “Company”) today announced it is advancing a project at its Mobile, Alabama refinery to produce crude-derived conventional Group III base oils through the Company’s existing hydrocracker and related processing infrastructure, providing lubricant manufacturers and blenders with an additional domestic source of high-quality Group III supply. The project is designed to add an incremental 6,000 barrels per day of conventional Group III production capacity and support production of 4 cSt, 6 cSt, and 8 cSt Group III base oils using an existing crude-derived hydrocracked vacuum gas oil stream produced at the Company’s Mobile, Alabama refinery. Combined with the Company’s existing re-refined Group III base oil production, this additional capacity is expected to make Vertex the leading Group III producer in North America. Vertex has completed preliminary design work and has procured a high-pressure lubricants hydrotreating unit. The Company plans to start pr
Taktile Secures $110M in Goldman Sachs-led Series C to Power AI Transformation in Financial Institutions24.6.2026 16:30:00 EEST | Press release
Taktile, the leader in AI transformation for financial institutions, today announced its $110 million Series C fundraise. Growth Equity at Goldman Sachs Alternatives led the round, with participation from Balderton Capital, Index Ventures, Tiger Global, Y Combinator, and Dig Ventures. Taktile Fast Facts Taktile enables banks and insurers to transform into AI-native organizations that are increasingly powered by autonomous agents. Demand for Taktile accelerated in 2025, as AI models became capable of automating high-stakes decisions that previously required hours of manual work—from underwriting business loans and assessing claims to catching financial crime. Customers automate and optimize decisions with Taktile by combining its financial services expertise and product built for sector-specific AI use cases. One of the world’s largest insurers is running multiple use cases on Taktile, with projected cost efficiencies of over $90M in claims processing alone. Taktile’s team has a proven
New MetLife Study Reveals a 72% “Confidence Gap” in Ability to Recover from Life's Setbacks24.6.2026 16:25:00 EEST | Press release
A new multinational study from MetLife reveals a striking “confidence gap”: while most adults describe themselves as resilient, their confidence drops by 72% when faced with real-life setbacks. The Confident Pathways Report, conducted across the United States, United Kingdom, Japan, and Mexico, was designed to better understand how confidence is built and sustained throughout life. The findings underscore the role of opportunity, preparedness, and support in building confidence - factors that help people navigate uncertainty, recover from setbacks and pursue their goals. At a time when soccer is bringing people and communities together around the world, the findings also highlight how early childhood experiences such as sports, education, and mentorship can help foster resilience and gain confidence from a young age. Key findings across the four countries surveyed include: Confidence drops by 72% when adults consider their ability to recover from setbacks. Respondents were far more lik
StatLab Launches CytoPath Disc, Advancing Standardized Cell Block Preparation Worldwide24.6.2026 16:08:00 EEST | Press release
StatLab Medical Products, a leading global developer and manufacturer of pathology supplies and equipment, today announced the global launch of the CytoPath Disc, an innovative cell block preparation technology designed to standardize and simplify cell block preparation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260624368623/en/ Developed as an alternative to traditional cell block methods, which convert concentrated cells suspended in fluid into a paraffin-embedded format for slide-based evaluation, the patent‑pending CytoPath Disc offers a more streamlined and efficient approach. The CytoPath Disc absorbs concentrated cells within a simple, sponge-like matrix, which is then processed, embedded, stained, and sectioned using standard histology workflows. Traditional cell block preparation methods often present challenges in achieving consistent results due to complex procedures, as well as the need for additional equipm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom